CorriXR Therapeutics, Inc. — Form D/A

CorriXR Therapeutics, Inc. of Newark, DE, a company, filed a Form D amendment with the SEC on 2024-01-29. The offering totals $8.0M, of which $6.5M was reported sold. Industry: Biotechnology.

Offering

Filed: 2024-01-29
Form: D/A
Accession: 0001938281-24-000001
Industry: Biotechnology
Exemptions: 06b
Total offering: $8.0M
Amount sold: $6.5M
Remaining: $1.5M
Investors: 4
Date of first sale: 2022-06-30
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-452572

Issuer

Name: CorriXR Therapeutics, Inc.
CIK: 0001938281
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2022
Address: 550 S. College Avenue, Suite 107, Newark, DE, 19713
Phone: 302-623-5305

Officers, directors & promoters (8)

Name	Role	Location
Jeffrey Carper	Director	Newark, DE
Eric Kmiec	Director	Newark, DE
Deborah Moorad	Director	Newark, DE
Janice Nevin	Director	Newark, DE
Stella Vnook	Director	Kenmore, NY
Jon Brilliant	Executive Officer	Baltimore, MD
Eric Kmiec	Executive Officer	Newark, DE
Deborah Moorad	Executive Officer	Newark, DE

Other filings by this issuer (1)

Filed	Form	Offering	Sold
2022-07-15	D	$8.0M	$2.5M

More